程序性死亡分子-1及其配体在非小细胞肺癌中的治疗进展

Abstract
Figure/Table
References (31)
Related Citation (15)

Download: PDF (649 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The traditional treatment of lung cancer is not satisfactory, so it is urgent to explore new therapy to break the bottleneck. Immunotherapy is a new treatment with low toxicity and high specificity. Suppressing the PD-1/PD-L1 pathway is considered as one of the most promising treatments. A number of studies reported that blockade of PD-1 and its ligand PD-L1 achieved favorable outcomes for advanced non-small cell lung cancer patients. Nonetheless, the anti-PD-1/PD-L1 antibody as monotherapy or in combination with other antineoplastic therapy in non-small cell lung cancer remains controversial. In this article, we reviewes the current state of research and advancement of PD-1/PD-L1 in the treatment of non-small cell lung cancer.

Key words： PD-1 PD-L1 Immunotherapy Non-small cell lung cancer

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yi1 YANG Ze1 BAI Yuju1 MA Hu1
	2
	3

Cite this article:

WANG Yi1 YANG Ze1 BAI Yuju1 MA Hu1,2,3. Progression of PD-1/PD-L1 in non-small cell lung cancer therapy[J]. 中国医药导报, 2017, 14(15): 39-42,54.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I15/39

[1] Rebecca L，Kimberly D，Ahmedin J. Cancer statistics [J]. CA Cancer J Clin，2017，67：7-30.
[2] Topalian SL，Hodi FS，Brahmer JR，et al. Safety，activity，and immune correlates of anti PD-1 antibody in cancer [J]. N Engl J Med，2012，366（26）：2443-2454.
[3] Ramsay AG. Immune checkpoint blockade immunotherapy to activate antitumour T-cell immunity [J]. Br J Haematol，2013，162（3）：313-325.
[4] Taube JM. Unleashing the immune system：PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade [J]. Oncoimmunology，2014，3（11）：e963413.
[5] Gettinger SN，Hellmann MD，Shepherd FA，et al. First-line mono-therapy with nivolumab（NIVO；anti-programmed death-1 [PD-1]）in advanced non-small cell lung cancer（NSCLC）：safety，efficacy and correlation of outcomes with PD-1 ligand（PD-L1）expression [J]. J Clin Oncol，2015，33（15 Suppl）：8025.
[6] Garon EB，Rizvi NA，Hui R，et al. Pembrolizumab for the treatment of non-small-cell lung cancer [J]. N Engl J Med，2015，372（21）：2018-2028.
[7] Herbst RS，Soria JC，Kowanetz M，et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J]. Nature，2014，515（7528）：563-567.
[8] Rizvi NA，Mazieres J，Planchard D，et al. Activity and safety of nivolumab，an anti-PD-1 immune checkpoint inhibitor，for patients with advanced，refractory squamous non-small-cell lung cancer （CheckMate063）：a phase 2，single-arm trial [J]. Lancet Oncol，2015，16（3）：257-265.
[9] Spigel DR，Reckamp KL，Rizvi NA，et al. A phase Ⅲ study （CheckMate 017） of nivolumab （NIVO；anti-programmed death-1 [PD-1]） vs docetaxel （DOC） in previously treated advanced or metastatic squamous （SQ） cell non-small cell lung cancer （NSCLC） [J]. J Clin Oncol，2015，33：2015.
[10] Paz-Ares L，Horn L，Borghaei H，et al. Phase Ⅲ，randomized trial （CheckMate 057） of nivolumab （NIVO） versus docetaxel （DOC） in advanced non-squamous cell （non-SQ） non-small cell lung cancer （NSCLC） [J]. J Clin Oncol，2015，33（18 Suppl）：LBA109.
[11] Brahmer J，Reckamp KL，Baas P，et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer [J]. N Engl J Med，2015，373（2）：123-135.
[12] Rizvi NA，Mazieres J，Planchard D，et al. Activity and safety of nivolumab，an anti-PD-1 immune checkpoint inhibitor，for patients with advanced，refractory squamous non-small-cell lung cancer （CheckMate 063）：a phase 2，single-arm trial [J]. Lancet Oncol，2015，16（3）：257-265.
[13] Socinski M，Creelan B，Horn L，et al. CheckMate 026：a phase 3 trial of nivolumab vs investigator′s choice of platinum-based doublet chemotherapy as first-line therapy for stage Ⅳ/recurrent programmed death ligand 1 （PD-L1）-positive NSCLC[C]//. 2016 ESMO Congress，Abstract LBA7_PR. 2016.
[14] Garon EB，Rizvi NA，Hui R，et al. Pembrolizumab for the treatment of non-small-cell lung cancer [J]. N Engl J Med，2015，372（21）：2018-2028.
[15] Reck M，Rodriguez-Abreu D，Robinson AG，et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer [J]. N Engl J Med，2016，375（19）：1823-1833.
[16] Fehrenbacher L，Spira A，Ballinger M，et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer（POPLAR）：a multicentre，open-label，phase 2 randomised controlled trial [J]. Lancet，2016，387（10030）：1837-1846.
[17] Rizvi NA，Chow LQM，Dirix LY，et al. Clinical trials of MPDL3280A （anti-PDL1） in patients （pts） with non-small cell lung cancer （NSCLC） [J]. J Clin Oncol，2014，32（15 Suppl）：TPS8123.
[18] Brahmer J，Reckamp KL，Baas P，et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer [J]. N Engl J Med，2015，373（2）：123-135.
[19] Langer CJ，Gadgeel SM，Borghaei H，et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced，non-squamous non-small-cell lung cancer：a randomised，phase 2 cohort of the open-label KEYNOTE-021 study [J]. Lancet Oncol，2016，17（11）：1497-1508.
[20] Liu SV，Powderly JD，Camidge DR，et al. Safety and efficacy of MPDL3280A （anti-PDL1） in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer （NSCLC）[J]. J Clin Oncol，2015，33（15 Suppl）：8030.
[21] Chen N，Fang W，Zhan J，et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC：implication for optional immune targeted therapy for NSCLC patients with EGFR mutation [J]. J Thorac Oncol，2015，10（6）：910-923.
[22] D’Incecco A，Andreozzi M，Ludovini V，et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients [J]. Br J Cancer，2015，112（1）：95-102.
[23] Creelan BC，Chow LQ，Kim D-W，et al. Safety and tolerability results from a phase I study of MEDI4736，a human IgG1 anti-programmed cell death-ligand-1 （PD-L1） antibody，combined with gefitinib in patients （pts） with non-small-cell lung cancer （NSCLC） [J]. J Clin Oncol，2015，33（15 Suppl）：3047.
[24] Rizvi NA，Chow LQM，Borghaei H，et al. Safety and response with nivolumab （ant-i PD-1；BMS-936558，ONO-4538） plus erlotinib in patients （pts） with epidermal growth factor receptor mutant （EGFR MT） advanced NSCLC [J]. J Clin Oncol，2014，32（5 Suppl）：8022.
[25] Rizvi NA，Antonia SJ，Shepherd FA，et al. Nivolumab （Anti-PD-1；BMS-936558，ONO-4538） maintenance as monot-herapy or in combination with bevacizumab （BEV） for non-small cell lung cancer （NSCLC） previously treated 2014， 90（5）：S32.
[26] Eli Lilly and Company. A study of the combination of necitu-mumab （LY3012211） andpembrolizumab （MK3475） in participants with NSCLC. Available from：https：//www.clinicaltrials.gov/ct2/show/NCT02451930. NLM identifier：NCT02451930. Accessed November 28，2015.
[27] Hatzi VI，Laskaratou DA，Mavragani IV，et al. Non-targeted radiation effects in vivo：a critical glance of the future in radiobiology [J]. Cancer Lett，2015，356（1）：34-42.
[28] Golden EB，Demaria S，Schiff PB，et al. An absco-pal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer [J]. Cancer Immunol Res，2013，1（6）：365-372.
[29] Schaue D，Ratikan JA，Iwamoto KS，et al. Maximizing tumor immunity with fractionated radiation [J]. Int J Radiat Oncol Biol Phys，2012，83（4）：1306-1310.
[30] Anderson Cancer Center. MK-3475 and hypofractionated stereotactic radiation therapy in patientswithnon-small cell lung cancer （NSCLC）. Available from：https：//www.clinicaltrials.gov/ct2/show/NCT02444741. NLM identifier：NCT02444741. 2015.
[31] Yale University. Evaluating the combination of MK-3475 and sterotactic body radiotherapy in patients with metastatic melanoma or NSCLC. Available from：https：//www.clinicaltrials.gov/ct2/show/NCT02407171.NLM identifier：NCT024 07171. 2015.